Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)


An adenosine reuptake inhibitor (AdoRI) is a type of drug which acts as a reuptake inhibitor for the purine nucleoside and neurotransmitter adenosine by blocking the action of one or more of the equilibrative nucleoside transporters (ENTs).[1][2][3] This in turn leads to increased extracellular concentrations of adenosine and therefore an increase in adenosinergic neurotransmission.

Main article: Reuptake inhibitor

List of AdoRIsEdit

See also Edit

References Edit

  1. 1.0 1.1 1.2 1.3 SenGupta DJ, Unadkat JD. (2004). Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep.. Biochem Pharmacol. 67 (3): 453–458.
  2. Endres CJ, Sengupta DJ, Unadkat JD. (2004). Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1.. Biochem J. 380 (1): 131–137.
  3. Chaudary N, Naydenova Z, Shuralyova I, Coe IR. (2004). The adenosine transporter, mENT1, is a target for adenosine receptor signaling and protein kinase Cepsilon in hypoxic and pharmacological preconditioning in the mouse cardiomyocyte cell line, HL-1.. J Pharmacol Exp Ther. 310 (3): 1190–1198.
  4. 4.0 4.1 4.2 4.3 4.4 4.5 Goldfrank, Lewis R.; Neal Flomenbaum, Mary Ann Howland, Robert S. (2006). Goldfrank's toxicologic emergencies.
  5. 5.0 5.1 5.2 Narimatsu E, Niiya T, Kawamata M, Namiki A. (2006). [The mechanisms of depression by benzodiazepines, barbiturates and propofol of excitatory synaptic transmissions mediated by adenosine neuromodulation]. Masui. 55 (6): 684–691.
  6. Tohdoh Y, Narimatsu E, Kawamata M, Namiki A. (2000). The involvement of adenosine neuromodulation in pentobarbital-induced field excitatory postsynaptic potentials depression in rat hippocampal slices.. Anesth Analg. 91 (6): 1537–1541.
  7. Patel J, Marangos PJ, Skolnick P, Paul SM, Martino AM. (1982). Benzodiazepines are weak inhibitors of [3H]nitrobenzylthioinosine binding to adenosine uptake sites in brain.. Neurosci Lett. 29 (1): 79–82.
  8. York MJ, Davies LP. (1982). The effect of diazepam on adenosine uptake and adenosine-stimulated adenylate cyclase in guinea-pig brain.. Can J Physiol Pharmacol. 60 (3): 302–307.
  9. Ujfalusi A, Cseppentö A, Nagy E, Szabó JZ, Kovács P, Szentmiklósi AJ. (1999). Sensitization by chronic diazepam treatment of A2A adenosine receptor-mediated relaxation in rat pulmonary artery.. Life Sci. 64 (2): PL19–25.
  10. Narimatsu E, Niiya T, Kawamata M, Namiki A. (2008). Adenosine and adenosine uptake inhibitors potentiate the neuromuscular blocking action of rocuronium mediated by adenosine A(1) receptors in isolated rat diaphragms.. Acta Anaesthesiol Scand. 52 (10): 1415–1422.
  11. Bender AS, Hertz L. (1986). Similarities of adenosine uptake systems in astrocytes and neurons in primary cultures.. Neurochem Res. 11 (11): 1507–1524.
  12. O'Regan MH, Phillis JW. (1988). Potentiation of adenosine-evoked depression of rat cerebral cortical neurons by triazolam.. Brain Res. 445 (2): 376–379.
  13. 13.0 13.1 Phillis JW, Delong RE. (1984). A purinergic component in the central actions of meprobamate.. Eur J Pharmacol. 101 (3-4): 295–297.
  14. 14.0 14.1 DeLong RE, Phillis JW, Barraco RA. (1985). A possible role of endogenous adenosine in the sedative action of meprobamate.. Eur J Pharmacol. 118 (3): 359–362.
  15. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH. (2009). [Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies.. J Pharmacol Exp Ther. 329 (2): 827–837.
  16. Wang S, Cone J, Fong M, Yoshitake M, Kambayashi Ji, Liu Y. (2001). Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication.. J Cardiovasc Pharmacol. 38 (5): 775–783.
  17. 17.0 17.1 17.2 17.3 17.4 Phillis JW, Wu PH. (1982). The effect of various centrally active drugs on adenosine uptake by the central nervous system.. Comp Biochem Physiol C. 72 (2): 179–187.
  18. 18.0 18.1 Phillis JW. (1984). Potentiation of the action of adenosine on cerebral cortical neurones by the tricyclic antidepressants.. Br J Pharmacol. 83 (2): 567–575.
  19. Stein MB, Black B, Brown TM, Uhde TW. (1993). Lack of efficacy of the adenosine reuptake inhibitor dipyridamole in the treatment of anxiety disorders.. Biol Psychiatry. 33 (8-9): 647–650.
  20. 20.0 20.1 Phillis JW, Bender AS, Marszalec W. (1985). Estradiol and progesterone potentiate adenosine's depressant action on rat cerebral cortical neurons.. Gen Pharmacol 16 (6): 609–612.
  21. Allen-Gipson DS, Jarrell JC, Bailey KL, Robinson JE, Kharbanda KK, Sisson JH, Wyatt TA. (2009). Ethanol Blocks Adenosine Uptake via Inhibiting the Nucleoside Transport System in Bronchial Epithelial Cells.. Alcohol Clin Exp Res. 33 (5): 791–8.
  22. Verma A, Houston M, Marangos PJ. (1985). Solubilization of an adenosine uptake site in brain.. J Neurochem. 45 (2): 596–603.
  23. 23.0 23.1 Phillis JW, Wu PH, Coffin VL. (1983). Inhibition of adenosine uptake into rat brain synaptosomes by prostaglandins, benzodiazepines and other centrally active compounds.. Gen Pharmacol. 14 (5): 475–479.
  24. Ngai AC, Monsen MR, Ibayashi S, Ko KR, Winn HR. (1989). Effect of inosine on pial arterioles: potentiation of adenosine-induced vasodilation.. Am J Physiol. 256 (3 (Pt2)): H603–H606.
  25. Noji T, Nan-ya K, Mizutani M, Katagiri C, Sano J, Takada C, Nishikawa S, Karasawa A, Kusaka H. (2002). KF24345, an adenosine uptake inhibitor, ameliorates the severity and mortality of lethal acute pancreatitis via endogenous adenosine in mice.. Eur J Pharmacol. 454 (1): 85–93.
  26. Lee CM, Cheung WT. (1985). Inhibitory effect of adenosine on electrically evoked contractions in the rat vas deferens: pharmacological characterization.. Neurosci Lett. 59 (1): 47–52.
  27. Marangos PJ, Patel J, Clark-Rosenberg R, Martino AM. (1982). [3H]nitrobenzylthioinosine binding as a probe for the study of adenosine uptake sites in brain.. J Neurochem. 39 (1): 184–191.
  28. Coffin VL, Taylor JA, Phillis JW, Altman HJ, Barraco RA. (1984). Behavioral interaction of adenosine and methylxanthines on central purinergic systems.. Neurosci Lett. 47 (2): 91–98.
  29. Shi D, Daly JW. (1999). Chronic effects of xanthines on levels of central receptors in mice.. Cell Mol Neurobiol. 19 (6): 719–732.
  30. Phillis JW. (1985). Chlorpromazine and trifluoperazine potentiate the action of adenosine on rat cerebral cortical neurons.. Gen Pharmacol. 16 (1): 19–24.
  31. Phillis JW. (1984). Interactions of the anticonvulsants diphenylhydantoin and carbamazepine with adenosine on cerebral cortical neurons.. Epilepsia. 25 (6): 765–772.
  32. Andiné P, Rudolphi KA, Fredholm BB, Hagberg H. (1990). Effect of propentofylline (HWA 285) on extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient ischaemia.. Br J Pharmacol. 100 (4): 814–818.
  33. Ohmori H, Sato Y, Namiki A. (2004). The anticonvulsant action of propofol on epileptiform activity in rat hippocampal slices.. Anesth Analg. 99 (4): 1095–1101.
  34. Noji T, Nan-ya K, Katagiri C, Mizutani M, Sano J, Nishikawa S, Karasawa A, Kusaka H. (2002). Adenosine uptake inhibition ameliorates cerulein-induced acute pancreatitis in mice.. Pancreas. 25 (4): 387–392.
  35. Gresele P, Arnout J, Deckmyn H, Vermylen J. (1986). Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity.. Thromb Haemost. 55 (1): 12–18.
  36. Bauman LA, Mahle CD, Boissard CG, Gribkoff VK. (1992). Age-dependence of effects of A1 adenosine receptor antagonism in rat hippocampal slices.. J Neurophysiol. 68 (2): 629–638.
  37. Boissard CG, Gribkoff VK. (1993). The effects of the adenosine reuptake inhibitor soluflazine on synaptic potentials and population hypoxic depolarizations in area CA1 of rat hippocampus in vitro.. Neuropharmacology. 32 (2): 149–155.


This page uses Creative Commons Licensed content from Wikipedia (view authors).
Community content is available under CC-BY-SA unless otherwise noted.